Breast Cancer RNA-Seq and Clinical Data from Two Population-Based Cohorts

RNA-Seq data from 270 tumors in Cohort270 and 3,271 tumors in the SCAN-B cohort, used to study immunoglobulin gene expression and its association with prognosis in early breast cancer. The data was generated by researchers at Lund University and is publicly available via NCBI GEO and figshare. The study was approved by the Lund Regional Ethical Review Board.

Use Cases

• Assessing the prognostic value of IGJ and IGH chain RNA expression levels in breast cancer based on the study's methodology.
• Correlating tumor characteristics and patient clinical data with immunoglobulin expression signatures as described in the source article.
• Validating findings on independent breast cancer cohorts using the publicly available RNA-Seq and clinical data from GEO.
• Replicating Kaplan-Meier survival analyses related to immunoglobulin expression using the provided R code.

Strengths

• Data originates from two distinct population-based breast cancer cohorts, totaling over 3,500 tumor samples.
• Includes both RNA-Seq expression data and linked clinical/tumor characteristic data for analysis.
• Publicly accessible via persistent identifiers in established repositories (NCBI GEO, figshare, cBioPortal).
• Study methodology and ethical approvals are explicitly documented.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the primary data files is unknown, which may limit suitability assessment.
• Last update date is unknown; freshness unverified.

Provenance

Source

NCBI Gene Expression Omnibus (GEO), figshare, and cBioPortal for Cancer Genomics.

Collection Method

RNA sequencing of breast cancer tumor samples from two local population-based cohorts.

Geography

Likely Sweden (based on Lund Regional Ethical Review Board approval).